November 2, 2017 / 12:12 PM / 2 months ago

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

Nov 2 (Reuters) - Adaptimmune Therapeutics Plc

* Adaptimmune reports third quarter 2017 financial results and business updates

* Q3 revenue $27.2 million versus $2.4 million

* Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S

* Q3 loss per share $0.00

* Adaptimmune- existing cash, cash equivalents, securities, income from GSK on transition of NY-ESO program to fund operating plan through to early 2020​ Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below